{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:08:13Z","timestamp":1792001293635,"version":"4.4.0"},"reference-count":283,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2023,6,21]]},"abstract":"<jats:p>Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline.<\/jats:p>","DOI":"10.1128\/cmr.00059-22","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T14:00:40Z","timestamp":1681740040000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":107,"title":["Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections"],"prefix":"10.1128","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3972","authenticated-orcid":true,"given":"Kelly A.","family":"Cairns","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-2022","authenticated-orcid":false,"given":"Andrew A.","family":"Udy","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-2438","authenticated-orcid":false,"given":"Trisha N.","family":"Peel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-6127","authenticated-orcid":true,"given":"Iain J.","family":"Abbott","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Microbiology Unit, Alfred Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dooley","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-2126","authenticated-orcid":true,"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Infection Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia"},{"name":"Centre to Impact AMR, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-020-00737-2"},{"key":"e_1_3_2_3_2","volume-title":"Responding to the threat of antimicrobial resistance, Australia\u2019s first national antimicrobial resistance strategy 2015\u20132019.","author":"Australian Government","year":"2015","unstructured":"Australian Government. 2015. Responding to the threat of antimicrobial resistance, Australia\u2019s first national antimicrobial resistance strategy 2015\u20132019. Commonwealth of Australia, Canberra, ACT, Australia."},{"key":"e_1_3_2_4_2","volume-title":"Antibiotic resistance threats in the United States, 2019.","author":"CDC","year":"2019","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States, 2019. US Department of Health and Human Services, CDC, Atlanta, GA. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2021-0012"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz089"},{"key":"e_1_3_2_8_2","volume-title":"2021 antibacterial agents in clinical and preclinical development: an overview and analysis.","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-18"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100732"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2761"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2020.44.19"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2020.44.72"},{"key":"e_1_3_2_14_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 19 September 2002 access date. Expected resistant and susceptible phenotypes. https:\/\/www.eucast.org\/expert_rules_and_expected_phenotypes\/expected_phenotypes\/."},{"key":"e_1_3_2_15_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2022","unstructured":"Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing, 32nd ed. CLSI guideline M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"32"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.08.004"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1479397"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00145-1"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000283"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04206-9"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.08.030"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(88)91037-9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198807213190307"},{"key":"e_1_3_2_24_2","volume-title":"Australian Group on Antimicrobial Resistance Sepsis Outcomes Programs: 2019 report.","author":"Coombs G","year":"2021","unstructured":"Coombs G, Bell JM, Daley D, Collignon P, Cooley L, Gottlieb T, Iredell J, Warner M, Nimmo G, Robson J. on behalf of the Australian Group on Antimicrobial Resistance and Australian Commission on Safety and Quality in Health Care. 2021. Australian Group on Antimicrobial Resistance Sepsis Outcomes Programs: 2019 report. Australian Commission on Safety and Quality in Health Care, Sydney, Australia."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1769500"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2018.1516272"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2022.46.17"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01667-21"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.4065\/80.9.1215"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04376-2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1809"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v48i78a03"},{"key":"e_1_3_2_33_2","volume-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net)\u2014annual epidemiological report for 2020.","author":"European Centre for Disease Prevention and Control","year":"2022","unstructured":"European Centre for Disease Prevention and Control. 2022. Antimicrobial resistance in the EU\/EEA (EARS-Net)\u2014annual epidemiological report for 2020. European Centre for Disease Prevention and Control, Stockholm, Sweden. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2020. Accessed 27 September 2022."},{"key":"e_1_3_2_34_2","volume-title":"Additional tables\u2014antimicrobial resistance in the EU\/EEA 2020.","author":"European Centre for Disease Prevention and Control","year":"2022","unstructured":"European Centre for Disease Prevention and Control. 2022. Additional tables\u2014antimicrobial resistance in the EU\/EEA 2020. European Centre for Disease Prevention and Control, Stockholm, Sweden. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/EUEEA_trend_tables_for_individual_isolates_2020.pdf. Accessed 27 September 2022."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab185"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf246"},{"key":"e_1_3_2_37_2","first-page":"560","article-title":"Vancomycin resistant Enterococcus faecium infection in a liver transplant recipient","volume":"25","author":"Kamarulzaman A","year":"1995","unstructured":"Kamarulzaman A, Tosolini FA, Boquest AL, Geddes JE, Richards MJ. 1995. Vancomycin resistant Enterococcus faecium infection in a liver transplant recipient. Aust N Z J Med 25:560.","journal-title":"Aust N Z J Med"},{"key":"e_1_3_2_38_2","volume-title":"Australian Group on Antimicrobial Resistance Sepsis Outcomes Programs: 2020 report.","author":"Coombs G","year":"2021","unstructured":"Coombs G, Bell JM, Daley D, Collignon P, Cooley L, Gottlieb T, Iredell J, Warner M, Nimmo G, Robson J. on behalf of the Australian Group on Antimicrobial Resistance and Australian Commission on Safety and Quality in Health Care. 2021. Australian Group on Antimicrobial Resistance Sepsis Outcomes Programs: 2020 report. Australian Commission on Safety and Quality in Health Care, Sydney, Australia."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.017"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000916"},{"key":"e_1_3_2_41_2","volume-title":"Vancomycin-resistant enterococci, 2020.","author":"Institute of Environmental Science and Research Ltd","year":"2020","unstructured":"Institute of Environmental Science and Research Ltd. 2020. Vancomycin-resistant enterococci, 2020. Institute of Environmental Science and Research Ltd, Porirua, New Zealand. https:\/\/surv.esr.cri.nz\/PDF_surveillance\/Antimicrobial\/VRE\/VRE_2020.pdf. Accessed 12 October 2022."},{"key":"e_1_3_2_42_2","volume-title":"Vancomycin-resistant enterococci, 2019.","author":"Institute of Environmental Science and Research Ltd","year":"2019","unstructured":"Institute of Environmental Science and Research Ltd. 2019. Vancomycin-resistant enterococci, 2019. Institute of Environmental Science and Research Ltd, Porirua, New Zealand. https:\/\/surv.esr.cri.nz\/PDF_surveillance\/Antimicrobial\/VRE\/VRE_2019.pdf. Accessed 12 October 2022."},{"key":"e_1_3_2_43_2","volume-title":"Vancomycin-resistant enterococci (VRE) confirmed in 2008.","author":"Institute of Environmental Science and Research Ltd","year":"2008","unstructured":"Institute of Environmental Science and Research Ltd. 2008. Vancomycin-resistant enterococci (VRE) confirmed in 2008. Institute of Environmental Science and Research Ltd, Porirua, New Zealand. https:\/\/surv.esr.cri.nz\/PDF_surveillance\/Antimicrobial\/VRE\/VRE_2008.pdf. Accessed 12 October 2022."},{"key":"e_1_3_2_44_2","volume-title":"Vancomycin-resistant enterococci, 2017.","author":"Institute of Environmental Science and Research Ltd","year":"2017","unstructured":"Institute of Environmental Science and Research Ltd. 2017. Vancomycin-resistant enterococci, 2017. Institute of Environmental Science and Research Ltd, Porirua, New Zealand. https:\/\/surv.esr.cri.nz\/PDF_surveillance\/Antimicrobial\/VRE\/VRE_2017.pdf. Accessed 12 October 2022."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy657"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23916"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2021.0034"},{"key":"e_1_3_2_48_2","volume-title":"Antibiogram 2020.","author":"National Antimicrobial Resistance Surveillance Center","year":"2021","unstructured":"National Antimicrobial Resistance Surveillance Center. 2021. Antibiogram 2020. National Antimicrobial Resistance Surveillance Center, Nonthaburi, Thailand. http:\/\/narst.dmsc.moph.go.th\/antibiograms\/2020\/12\/Jan-Dec2020-Blood.pdf. Accessed 21 September 2022."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2002.1375"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.5.637"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw246"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12784"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13747"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01501-13"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.09.019"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2019.12.007"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1086\/502416"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2020.06.219"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.1003557"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.02.064"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz031"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.01.078"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0808-y"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2006.04.205"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03591.x"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1126"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1086\/520311"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.993"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00136-4"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1086\/502550"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz473"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1622-z"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.05.003"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.228"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.45.2001628"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2017.02.006"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1228"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab616"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac164"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03607-z"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12132"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001127"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.03.011"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00283-08"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01951-13"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.10.023"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac200"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9093055"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-017-0291-z"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.06.010"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.10.008"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.5.888"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.776"},{"key":"e_1_3_2_94_2","first-page":"291","article-title":"Treatment of vancomycin-resistant enterococcal bacteremia using combination therapy","volume":"16","author":"Dominguez ER","year":"1999","unstructured":"Dominguez ER, Diaz A, Greene J, Sandin RL. 1999. Treatment of vancomycin-resistant enterococcal bacteremia using combination therapy. Infect Med 16:291\u2013293.","journal-title":"Infect Med"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.760"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.794"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1137"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1086\/515002"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440210097010"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2069"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1904"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80270-8"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00030-13"},{"key":"e_1_3_2_104_2","volume-title":"Cubicin RF product information.","author":"Merck Sharp & Dohme","year":"2022","unstructured":"Merck Sharp & Dohme. 2022. Cubicin RF product information. Merck Sharp & Dohme, Rahway, NJ. https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/34c1faa3-a3d8-4fe6-8ca1-7016c17339d2\/spl-doc?hl=daptomycin#S13.2."},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1086\/430352"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.09.004"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky072"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw815"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix024"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.07.018"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw173"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02943-14"},{"key":"e_1_3_2_113_2","volume-title":"The Sanford guide to antimicrobial therapy.","author":"Antimicrobial Therapy Inc","year":"2022","unstructured":"Antimicrobial Therapy Inc. 2022. Enterococcus faecium. In The Sanford guide to antimicrobial therapy. Mobile application software. Antimicrobial Therapy Inc, Sperryville, VA."},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz081"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.027"},{"key":"e_1_3_2_116_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2021. Epidemiological cut-off values (ECOFF) and tentative epidemiological cut-off values (TECOFF). https:\/\/mic.eucast.org\/."},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.04.008"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113710"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00315-18"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy287"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1298"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-66"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac065"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0158-8"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10040446"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9010-17"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ501"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00015"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg248"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3484-3489.2002"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks201"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0060-3"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00714-13"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0687-9"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01289-13"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1047"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00031"},{"key":"e_1_3_2_138_2","volume-title":"Sivextro (tedizolid phosphate) prescribing information.","author":"Cubist Pharmaceuticals","year":"2014","unstructured":"Cubist Pharmaceuticals. 2014. Sivextro (tedizolid phosphate) prescribing information. Cubist Pharmaceuticals, Lexington, MA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205435s000lbl.pdf. Accessed 15 July 2022."},{"key":"e_1_3_2_139_2","volume-title":"Zyvox (linezolid) prescribing information.","author":"Pfizer Inc","year":"2013","unstructured":"Pfizer Inc. 2013. Zyvox (linezolid) prescribing information. Pfizer Inc, New York, NY. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021130s032,021131s026,021132s031lbl.pdf. Accessed 27 September 2022."},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00027-20"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.08.023"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12797"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-17"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2835"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000324"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc13984"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02490-20"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.01.012"},{"key":"e_1_3_2_149_2","volume-title":"Targocid (teicoplanin) product information.","author":"Sanofi-Aventis Australia Pty Ltd","year":"2023","unstructured":"Sanofi-Aventis Australia Pty Ltd. 2023. Targocid (teicoplanin) product information. Sanofi-Aventis Australia Pty Ltd, Macquarie Park, NSW, Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-06965-3&d=20220407172310101."},{"key":"e_1_3_2_150_2","volume-title":"Targocid 400 mg summary of product characteristics.","author":"Datapharm Ltd","year":"2022","unstructured":"Datapharm Ltd. 2022. Targocid 400 mg summary of product characteristics. Datapharm Ltd, Surrey, United Kingdom. https:\/\/www.medicines.org.uk\/emc\/medicine\/27321. Accessed 14 July 2022."},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.06.006"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.02.032"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00424-3"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-04952-5"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03652-6"},{"key":"e_1_3_2_156_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2020. EUCAST expert rules v 3.2 on Enterococcus spp. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Expert_Rules\/2020\/ExpertRules_V3.2_20190515_Enterococcus_revision_20200224.pdf. Accessed 7 April 2022."},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt130"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1834851"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365541003699623"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443040-00003"},{"key":"e_1_3_2_161_2","volume-title":"The Sanford guide to antimicrobial therapy.","author":"Antimicrobial Therapy Inc","year":"2022","unstructured":"Antimicrobial Therapy Inc. 2022. Quinupristin-dalfopristin. In The Sanford guide to antimicrobial therapy. Mobile application software. Antimicrobial Therapy Inc, Sperryville, VA."},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00212-10"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.017"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh144"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1086\/523588"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0077-7"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz479"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0156-z"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv156"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz545"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-017-0199-8"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01067-3"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01117-w"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_177_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_2_178_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018818094"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.12.004"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2020.241"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1435"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.020"},{"key":"e_1_3_2_184_2","volume-title":"Nuzyra (omadacycline) product information.","author":"Paratek Pharmaceuticals","year":"2018","unstructured":"Paratek Pharmaceuticals. 2018. Nuzyra (omadacycline) product information. Paratek Pharmaceuticals, Boston, MA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. Accessed 15 July 2022."},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab136"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1086\/517755"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1086\/340527"},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm542"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2019.00430"},{"key":"e_1_3_2_190_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15"},{"key":"e_1_3_2_191_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku530"},{"key":"e_1_3_2_192_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2001.00189.x"},{"key":"e_1_3_2_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.09.011"},{"key":"e_1_3_2_194_2","doi-asserted-by":"publisher","DOI":"10.1086\/502365"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210912119"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2016.02.006"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00734"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.08.023"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.059"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv319"},{"key":"e_1_3_2_202_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt294"},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06439-11"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02790-13"},{"key":"e_1_3_2_205_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00053-15"},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv007"},{"key":"e_1_3_2_207_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02274-13"},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011138"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00745-18"},{"key":"e_1_3_2_210_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19986-8"},{"key":"e_1_3_2_211_2","volume-title":"Molecular mechanisms of antimicrobial resistance in multi-drug resistant enterococci.","author":"Khan A","year":"2020","unstructured":"Khan A. 2020. Molecular mechanisms of antimicrobial resistance in multi-drug resistant enterococci. PhD thesis. The University of Texas, Houston, TX."},{"key":"e_1_3_2_212_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M324"},{"key":"e_1_3_2_213_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.236"},{"key":"e_1_3_2_214_2","doi-asserted-by":"publisher","DOI":"10.1177\/00185787211032364"},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02099-12"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-16"},{"key":"e_1_3_2_217_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac023"},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1086\/517221"},{"key":"e_1_3_2_219_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00011286"},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2012.717711"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1664-1665.2005"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa068"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00111-13"},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02344-14"},{"key":"e_1_3_2_225_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf066"},{"key":"e_1_3_2_226_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf207"},{"key":"e_1_3_2_227_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02074-19"},{"key":"e_1_3_2_228_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.24291"},{"key":"e_1_3_2_229_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-09"},{"key":"e_1_3_2_230_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl013"},{"key":"e_1_3_2_231_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr477"},{"key":"e_1_3_2_232_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106432"},{"key":"e_1_3_2_233_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.07.002"},{"key":"e_1_3_2_234_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200194030-00018"},{"key":"e_1_3_2_235_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02622-18"},{"key":"e_1_3_2_236_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04080.x"},{"key":"e_1_3_2_237_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"},{"key":"e_1_3_2_238_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.03.008"},{"key":"e_1_3_2_239_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx427"},{"key":"e_1_3_2_240_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00578-9"},{"key":"e_1_3_2_241_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14995"},{"key":"e_1_3_2_242_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106712"},{"key":"e_1_3_2_243_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.015"},{"key":"e_1_3_2_244_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000196"},{"key":"e_1_3_2_245_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P745"},{"key":"e_1_3_2_246_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0511-2"},{"key":"e_1_3_2_247_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.06.006"},{"key":"e_1_3_2_248_2","first-page":"30S","article-title":"Outpatient post-dialysis daptomycin prescription in an anephric hemodialysis (HD) patient: how much?","volume":"148","author":"Baeriswyl M","year":"2018","unstructured":"Baeriswyl M, Hemett OM, Erard V, Descombes E. 2018. Outpatient post-dialysis daptomycin prescription in an anephric hemodialysis (HD) patient: how much? Swiss Med Wkly 148:30S.","journal-title":"Swiss Med Wkly"},{"key":"e_1_3_2_249_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000740"},{"issue":"1","key":"e_1_3_2_250_2","first-page":"29","article-title":"Therapeutic drug monitoring of daptomycin in heart transplanted patient: a case report of osteoarticular infection with MRSA","volume":"23","author":"Verdier MC","year":"2009","unstructured":"Verdier MC, Tribut O, Revest M, Bentue-Ferrer D, Bellissant E. 2009. Therapeutic drug monitoring of daptomycin in heart transplanted patient: a case report of osteoarticular infection with MRSA. Fundam Clin Pharmacol 23(Suppl 1):29.","journal-title":"Fundam Clin Pharmacol"},{"key":"e_1_3_2_251_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01608-12"},{"key":"e_1_3_2_252_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(03)00119-6"},{"key":"e_1_3_2_253_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy749"},{"key":"e_1_3_2_254_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.11.002"},{"key":"e_1_3_2_255_2","doi-asserted-by":"publisher","DOI":"10.1086\/652767"},{"key":"e_1_3_2_256_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.05.013"},{"key":"e_1_3_2_257_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13061"},{"key":"e_1_3_2_258_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000710"},{"key":"e_1_3_2_259_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2019.09.002"},{"key":"e_1_3_2_260_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04050-9"},{"key":"e_1_3_2_261_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311"},{"key":"e_1_3_2_262_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342150-00007"},{"key":"e_1_3_2_263_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks153"},{"key":"e_1_3_2_264_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12806"},{"key":"e_1_3_2_265_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.051"},{"key":"e_1_3_2_266_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt133"},{"key":"e_1_3_2_267_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-2041-3"},{"key":"e_1_3_2_268_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.07.002"},{"key":"e_1_3_2_269_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz374"},{"key":"e_1_3_2_270_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2608.191499"},{"key":"e_1_3_2_271_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.023"},{"key":"e_1_3_2_272_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3180690755"},{"key":"e_1_3_2_273_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab499"},{"key":"e_1_3_2_274_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039030-00001"},{"key":"e_1_3_2_275_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2022. Clinical breakpoints and dosing of antibiotics. https:\/\/www.eucast.org\/clinical_breakpoints."},{"key":"e_1_3_2_276_2","unstructured":"Intralytix Inc. 2023. Safety and efficacy of oral administration of the phage cocktail VRELysin in healthy and VRE-colonized subjects. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05715619 (identifier NCT05715619). Accessed 2 March 2023."},{"key":"e_1_3_2_277_2","unstructured":"MicuRx. 2022. Contezolid acefosamil versus linezolid for the treatment of acute bacterial skin and skin structure infection. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03747497 (identifier NCT03747497). Accessed 2 March 2023."},{"key":"e_1_3_2_278_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01576-0"},{"key":"e_1_3_2_279_2","unstructured":"LegoChem Biosciences Inc. 2023. A phase 2a study effect of Vancomycin with vs without Delpazolid (LCB01-0371) in patients with MRSA bacteremia. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05225558 (identifier NCT05225558). Accessed 2 March 2023."},{"key":"e_1_3_2_280_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01184-17"},{"key":"e_1_3_2_281_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.05.012"},{"key":"e_1_3_2_282_2","unstructured":"Arpida AG. 2008. Phase 3 safety and efficacy study of I.V. iclaprim v linezolid in cSSSI (ASSIST-1). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00299520 (identifier NCT00299520). Accessed 2 March 2023."},{"key":"e_1_3_2_283_2","unstructured":"Arpida AG. 2007. Study of intravenous (I.V.) iclaprim versus linezolid in complicated skin and skin structure infections [cSSSI] (ASSIST-2). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00303550 (identifier NCT00303550). Accessed 2 March 2023."},{"key":"e_1_3_2_284_2","unstructured":"Arpida AG. 2009. Clinical efficacy of intravenous iclaprim versus Vancomycin in the treatment of hospital-acquired ventilator-associated or health-care-associated pneumonia. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00543608 (identifier NCT00543608). Accessed 2 March 2023."}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cmr.00059-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cmr.00059-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T13:03:13Z","timestamp":1687352593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/cmr.00059-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":283,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6,21]]}},"alternative-id":["10.1128\/cmr.00059-22"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00059-22","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"2023-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00059-22"}}